Fate Therapeutics

Yahoo Finance • 11 days ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immu... Full story

Yahoo Finance • 2 months ago

Fate Therapeutics’ SWOT analysis: biotech stock navigates clinical progress amid financial challenges

Fate Therapeutics, Inc. (NASDAQ:FATE), a biotechnology company specializing in programmed cellular immunotherapies for cancer and immune disorders, is navigating a critical juncture in its development pipeline. With a market capitalization... Full story

Yahoo Finance • 2 months ago

FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss

FATE THERAPEUTICS INC (NASDAQ:FATE [https://www.chartmill.com/stock/quote/FATE]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The clinical-stage biopharmaceutical compan... Full story

Yahoo Finance • 2 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus ery... Full story

Yahoo Finance • 2 months ago

Fate Therapeutics CEO Valamehr sells $15,396 in stock

Fate Therapeutics Inc (NASDAQ:FATE) President and CEO Bahram Valamehr sold 14,466 shares of common stock on August 4, 2025, according to a new SEC filing. The transaction comes as the stock has experienced a 9.4% decline over the past week... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5

Investing.com - H.C. Wainwright has reiterated its Neutral rating and $5.00 price target on Fate Therapeutics (NASDAQ:FATE), currently trading at $1.14, following the company’s presentation of FT819 data in lupus at the European Alliance o... Full story

Yahoo Finance • 4 months ago

Fate Therapeutics' SWOT analysis: promising data boosts stock outlook

Fate Therapeutics, Inc. (NASDAQ:FATE), a biotechnology company specializing in cellular immunotherapies, has been making significant strides in the development of treatments for cancer and autoimmune disorders. Recent clinical data and ana... Full story

Yahoo Finance • 4 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immuno... Full story

Yahoo Finance • 5 months ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf... Full story

Yahoo Finance • 5 months ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June Regenerative Medicine Advanced Therapy Desi... Full story

Yahoo Finance • 7 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T-cell Dose Expansion i... Full story

Yahoo Finance • 7 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular imm... Full story

Yahoo Finance • 8 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immu... Full story

Yahoo Finance • last year

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Are you a successful asset manager who has already amassed more than $1 billion in personal wealth? If not, there are probably a few things you can learn from the small list of folks who have. Luckily for us everyday investors, the Securi... Full story

Yahoo Finance • last year

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript May 11, 2024 Fate Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welco... Full story

Yahoo Finance • 2 years ago

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have Been Lifting Their Price Targets

It's been a good week for Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders, because the company has just released its latest yearly results, and the shares gained 4.5% to US$7.14. The results look positive overall; while revenues of US$6... Full story

Yahoo Finance • 2 years ago

Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results

Revenue: Reported $1.7 million for the fourth quarter of 2023. Operating Expenses: GAAP operating expenses were $49.8 million for the fourth quarter. Net Loss: Recorded a net loss of $44.1 million for the fourth quarter. Cash Position: End... Full story

Yahoo Finance • 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy IND Application Cleared b... Full story

Yahoo Finance • 2 years ago

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockho... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Ardelyx, Inc., Leslie’s, Inc., Enovix Corporation, and Fate Therapeutics, Inc. If you a... Full story